Immunohistologic Identification of Epstein‐Barr Virus‐Induced Hepatitis Reactivation after OKT‐3 Therapy following Orthotopic Liver Transplant

Rodney Smith Markin, R. P. Wood, B. W. Shaw, B. Brichacek, D. T. Purtilo

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Reactivated Epstein‐Barr virus infection associated with hepatitis appeared in a liver transplant patient receiving monoclonal OKT‐3 antibody for rejection. The histologic findings in liver biopsy specimens characteristic of allograft rejection were observed prior to and during the initial phase of antirejection therapy. However, failure of a complete response to antirejection therapy promoted rebiopsy. The specimen showed portal infiltrates composed predominantly of plasma cells and immunoblasts. The presumptive diagnosis of Ep‐stein‐Barr virus hepatitis was confirmed by staining frozen liver tissue for Epstein‐Barr virus nuclear‐associated antigen. OKT‐3 therapy was discontinued, and cycolsporine and steroid doses were reduced. Gradually, clinical features, serum aminotransferase and bilirubin levels, and the portal lymphoid infiltrate resolved. Epstein‐Barr virus serology showed an increase in convalescent titers IgG‐antiviral capsid antigen, and Epstein‐Barr virus nuclear‐associated antigen. The histologic, clinical, and laboratory features supporting the diagnosis of Epstein‐Barr virus hepatitis in a liver transplant patient are presented and discussed. This diagnosis guided appropriate therapy.

Original languageEnglish (US)
Pages (from-to)1014-1018
Number of pages5
JournalThe American journal of gastroenterology
Volume85
Issue number8
DOIs
StatePublished - Aug 1990

Fingerprint

Muromonab-CD3
Hepatitis
Transplants
Hepatitis Viruses
Liver
Viruses
Antigens
Immunosuppression
Capsid
Virus Diseases
Serology
Therapeutics
Transaminases
Plasma Cells
Bilirubin
Allografts
Steroids
Staining and Labeling
Biopsy
Serum

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Immunohistologic Identification of Epstein‐Barr Virus‐Induced Hepatitis Reactivation after OKT‐3 Therapy following Orthotopic Liver Transplant. / Markin, Rodney Smith; Wood, R. P.; Shaw, B. W.; Brichacek, B.; Purtilo, D. T.

In: The American journal of gastroenterology, Vol. 85, No. 8, 08.1990, p. 1014-1018.

Research output: Contribution to journalArticle

@article{1d88ae8468694eee9adc41c5f1d97a2a,
title = "Immunohistologic Identification of Epstein‐Barr Virus‐Induced Hepatitis Reactivation after OKT‐3 Therapy following Orthotopic Liver Transplant",
abstract = "Reactivated Epstein‐Barr virus infection associated with hepatitis appeared in a liver transplant patient receiving monoclonal OKT‐3 antibody for rejection. The histologic findings in liver biopsy specimens characteristic of allograft rejection were observed prior to and during the initial phase of antirejection therapy. However, failure of a complete response to antirejection therapy promoted rebiopsy. The specimen showed portal infiltrates composed predominantly of plasma cells and immunoblasts. The presumptive diagnosis of Ep‐stein‐Barr virus hepatitis was confirmed by staining frozen liver tissue for Epstein‐Barr virus nuclear‐associated antigen. OKT‐3 therapy was discontinued, and cycolsporine and steroid doses were reduced. Gradually, clinical features, serum aminotransferase and bilirubin levels, and the portal lymphoid infiltrate resolved. Epstein‐Barr virus serology showed an increase in convalescent titers IgG‐antiviral capsid antigen, and Epstein‐Barr virus nuclear‐associated antigen. The histologic, clinical, and laboratory features supporting the diagnosis of Epstein‐Barr virus hepatitis in a liver transplant patient are presented and discussed. This diagnosis guided appropriate therapy.",
author = "Markin, {Rodney Smith} and Wood, {R. P.} and Shaw, {B. W.} and B. Brichacek and Purtilo, {D. T.}",
year = "1990",
month = "8",
doi = "10.1111/j.1572-0241.1990.tb06799.x",
language = "English (US)",
volume = "85",
pages = "1014--1018",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Immunohistologic Identification of Epstein‐Barr Virus‐Induced Hepatitis Reactivation after OKT‐3 Therapy following Orthotopic Liver Transplant

AU - Markin, Rodney Smith

AU - Wood, R. P.

AU - Shaw, B. W.

AU - Brichacek, B.

AU - Purtilo, D. T.

PY - 1990/8

Y1 - 1990/8

N2 - Reactivated Epstein‐Barr virus infection associated with hepatitis appeared in a liver transplant patient receiving monoclonal OKT‐3 antibody for rejection. The histologic findings in liver biopsy specimens characteristic of allograft rejection were observed prior to and during the initial phase of antirejection therapy. However, failure of a complete response to antirejection therapy promoted rebiopsy. The specimen showed portal infiltrates composed predominantly of plasma cells and immunoblasts. The presumptive diagnosis of Ep‐stein‐Barr virus hepatitis was confirmed by staining frozen liver tissue for Epstein‐Barr virus nuclear‐associated antigen. OKT‐3 therapy was discontinued, and cycolsporine and steroid doses were reduced. Gradually, clinical features, serum aminotransferase and bilirubin levels, and the portal lymphoid infiltrate resolved. Epstein‐Barr virus serology showed an increase in convalescent titers IgG‐antiviral capsid antigen, and Epstein‐Barr virus nuclear‐associated antigen. The histologic, clinical, and laboratory features supporting the diagnosis of Epstein‐Barr virus hepatitis in a liver transplant patient are presented and discussed. This diagnosis guided appropriate therapy.

AB - Reactivated Epstein‐Barr virus infection associated with hepatitis appeared in a liver transplant patient receiving monoclonal OKT‐3 antibody for rejection. The histologic findings in liver biopsy specimens characteristic of allograft rejection were observed prior to and during the initial phase of antirejection therapy. However, failure of a complete response to antirejection therapy promoted rebiopsy. The specimen showed portal infiltrates composed predominantly of plasma cells and immunoblasts. The presumptive diagnosis of Ep‐stein‐Barr virus hepatitis was confirmed by staining frozen liver tissue for Epstein‐Barr virus nuclear‐associated antigen. OKT‐3 therapy was discontinued, and cycolsporine and steroid doses were reduced. Gradually, clinical features, serum aminotransferase and bilirubin levels, and the portal lymphoid infiltrate resolved. Epstein‐Barr virus serology showed an increase in convalescent titers IgG‐antiviral capsid antigen, and Epstein‐Barr virus nuclear‐associated antigen. The histologic, clinical, and laboratory features supporting the diagnosis of Epstein‐Barr virus hepatitis in a liver transplant patient are presented and discussed. This diagnosis guided appropriate therapy.

UR - http://www.scopus.com/inward/record.url?scp=0025357783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025357783&partnerID=8YFLogxK

U2 - 10.1111/j.1572-0241.1990.tb06799.x

DO - 10.1111/j.1572-0241.1990.tb06799.x

M3 - Article

C2 - 2165351

AN - SCOPUS:0025357783

VL - 85

SP - 1014

EP - 1018

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 8

ER -